Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 148 articles: HTML format

Single Articles

September 2026
1. LIM PO
   Cardiovascular outcomes in coronary microvascular dysfunction: the Multicenter FLOW-CMD Registry.
   Lancet. 2026;408:1173.
   PubMed    
   
   
   
2. LEE JM, Lee SH, Gim DH
   Cardiovascular outcomes in coronary microvascular dysfunction: the Multicenter FLOW-CMD Registry - Authors' reply.
   Lancet. 2026;408:1173-1174.
   PubMed    
   
   
   
3. CHANG CC, Tsai TY, Serruys PW
   Cardiovascular outcomes in coronary microvascular dysfunction: the Multicenter FLOW-CMD Registry.
   Lancet. 2026;408:1172-1173.
   PubMed    
   
   
   
4. BRAZILE TL, Conrad N, Bergman L, Gnanaraj JP, et al
   Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care.
   Lancet. 2026;408:935-951.
   PubMed     Abstract available
   
   
   
5. PABON MA, Smith G, Sharma G, Catov J, et al
   Adverse pregnancy outcomes and long-term cardiovascular disease risk.
   Lancet. 2026;408:952-968.
   PubMed     Abstract available
   
   
   
6. THE LANCET
   Reimagining maternal cardiovascular health.
   Lancet. 2026;408:867.
   PubMed    
   
   
   August 2026
7. SILVAIN J, Choi KH, Monguillon V, Kang D, et al
   Discontinuation of beta-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
   Lancet. 2026 Aug 30:S0140-6736(26)01426-1. doi: 10.1016/S0140-6736(26)01426.
   PubMed     Abstract available
   
   
   
8. IBANEZ B
   Stopping beta-blockers long after myocardial infarction.
   Lancet. 2026 Aug 30:S0140-6736(26)01650-8. doi: 10.1016/S0140-6736(26)01650.
   PubMed    
   
   
   
9. BOEDDINGHAUS J, Bima P, Crisanti L, Keller DI, et al
   Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial.
   Lancet. 2026 Aug 29:S0140-6736(26)01654-5. doi: 10.1016/S0140-6736(26)01654.
   PubMed     Abstract available
   
   
   
10. KANG J, Yang HM, Park S, Park KW, et al
    Reappraising long-term antiplatelet therapy after percutaneous coronary intervention - Authors' reply.
    Lancet. 2026;408:695-696.
    PubMed    
    
    
    
11. KHANNA S, Surreys PW, Bhat A
    Reappraising long-term antiplatelet therapy after percutaneous coronary intervention.
    Lancet. 2026;408:695.
    PubMed    
    
    
    July 2026
12. RUEL M, Nambala S, Guo MH, Verevkin A, et al
    Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.
    Lancet. 2026 Jul 31:S0140-6736(26)01288-2. doi: 10.1016/S0140-6736(26)01288.
    PubMed     Abstract available
    
    
    
13. ZHU Y, Gaudino M, Zhao Q
    Physiology-guided coronary artery bypass grafting in valve surgery - Authors' reply.
    Lancet. 2026;408:218.
    PubMed    
    
    
    
14. MAGOULIOTIS DE, Sicouri S, Ramlawi B
    Physiology-guided coronary artery bypass grafting in valve surgery.
    Lancet. 2026;408:217-218.
    PubMed    
    
    
    
15. LIP GYH, Kuzma L
    Combination antithrombotic therapy in atrial fibrillation after coronary interventions: shorter duration, more safety?
    Lancet. 2026 Jul 15:S0140-6736(26)00747-6. doi: 10.1016/S0140-6736(26)00747.
    PubMed    
    
    
    
16. SOTOMI Y, Kozuma K, Higuchi Y, Nakazawa G, et al
    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
    Lancet. 2026 Jul 15:S0140-6736(26)00665-3. doi: 10.1016/S0140-6736(26)00665.
    PubMed     Abstract available
    
    
    May 2026
17. ESCANED J, Mejia-Renteria H
    Microvascular dysfunction in atherosclerotic coronary disease.
    Lancet. 2026 May 21:S0140-6736(26)00862-7. doi: 10.1016/S0140-6736(26)00862.
    PubMed    
    
    
    
18. LEE JM, Lee SH, Gim DH, Lee SY, et al
    Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.
    Lancet. 2026 May 21:S0140-6736(26)00666-5. doi: 10.1016/S0140-6736(26)00666.
    PubMed     Abstract available
    
    
    April 2026
19. ZENG G, Bidel Z, Yang Q, Canoy D, et al
    Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
    Lancet. 2026;407:1626-1638.
    PubMed     Abstract available
    
    
    
20. MANGALESH S, Theodoropoulos P, Chi KY, Nanna MG, et al
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.
    Lancet. 2026;407:1601.
    PubMed    
    
    
    
21. TONDT J, Chinchilli VM
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.
    Lancet. 2026;407:1601.
    PubMed    
    
    
    
22. DEANFIELD J, Emerson SS, Rasmussen S, Stensen S, et al
    Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.
    Lancet. 2026;407:1601-1602.
    PubMed    
    
    
    
23. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    PubMed    
    
    
    
24. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    PubMed    
    
    
    
25. SUN Y, Guo X
    Cardiovascular benefit of blood-pressure lowering in chronic kidney disease.
    Lancet. 2026;407:1578-1580.
    PubMed    
    
    
    
26. VAN DER BIJL P, Bax JJ
    Contemporary non-invasive imaging for coronary artery disease - Authors' reply.
    Lancet. 2026;407:1425.
    PubMed    
    
    
    
27. HUNYOR I, Wilcox I, O'Sullivan J
    Contemporary non-invasive imaging for coronary artery disease.
    Lancet. 2026;407:1424.
    PubMed    
    
    
    
28. ZHENG H
    Contemporary non-invasive imaging for coronary artery disease.
    Lancet. 2026;407:1424.
    PubMed    
    
    
    
29. HOLCK EN, Holm NR, Hildick-Smith D, Lindsay MM, et al
    Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.
    Lancet. 2026;407:1374-1382.
    PubMed     Abstract available
    
    
    March 2026
30. CHIARITO M, Tartaglia F
    Moving beyond aspirin after percutaneous coronary intervention: 10-year results from the HOST-EXAM trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00562-3. doi: 10.1016/S0140-6736(26)00562.
    PubMed    
    
    
    
31. GAROT P, Akodad M
    Coronary revascularisation before TAVI.
    Lancet. 2026 Mar 29:S0140-6736(26)00597-0. doi: 10.1016/S0140-6736(26)00597.
    PubMed    
    
    
    
32. DELEWI R, Aarts HM, Broeze GM, Hemelrijk KI, et al
    Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00308-9. doi: 10.1016/S0140-6736(26)00308.
    PubMed     Abstract available
    
    
    
33. KANG J, Park S, Yang HM, Shin ES, et al
    Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00422-8. doi: 10.1016/S0140-6736(26)00422.
    PubMed     Abstract available
    
    
    
34. ZHU Y, Cheng Z, Zhao Y, Han L, et al
    Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-
    Lancet. 2026;407:1161-1170.
    PubMed     Abstract available
    
    
    
35. STEINHAUER R, Xu JYH, Blumenthal RS, Troy AL, et al
    Early atheroma prevention: a cost-effective approach to healthy cardiovascular ageing.
    Lancet. 2026 Mar 16:S0140-6736(26)00419-8. doi: 10.1016/S0140-6736(26)00419.
    PubMed    
    
    
    February 2026
36. VALGIMIGLI M, Gragnano F, Giacoppo D
    Clopidogrel versus aspirin for coronary artery disease - Authors' reply.
    Lancet. 2026;407:853-854.
    PubMed    
    
    
    
37. IBRAHIM A, Shalabi L, Ando G
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:853.
    PubMed    
    
    
    
38. DELLO RUSSO C, Venetucci L, Ramlogan R, Gagliardi D, et al
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:852-853.
    PubMed    
    
    
    
39. COLLI A, Casazza G, Gluud C
    Clopidogrel versus aspirin for coronary artery disease.
    Lancet. 2026;407:851-852.
    PubMed    
    
    
    
40. XIONG Y, Alemseged F, Cao Z, Schwamm LH, et al
    Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.
    Lancet. 2026 Feb 5:S0140-6736(25)02633-9. doi: 10.1016/S0140-6736(25)02633.
    PubMed     Abstract available
    
    
    
41. TSIVGOULIS G, Palaiodimou L, Turc G
    Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion.
    Lancet. 2026 Feb 5:S0140-6736(26)00139-X. doi: 10.1016/S0140-6736(26)00139.
    PubMed    
    
    
    January 2026
42. WENZL FA, Ow KW, Velders MA, Tyrer F, et al
    Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
    Lancet. 2026;407:515-528.
    PubMed     Abstract available
    
    
    
43. LIU JE, Feldman DN
    Cancer and acute coronary syndrome: from risk assessment to personalised clinical decision making.
    Lancet. 2026;407:474-475.
    PubMed    
    
    
    
44. KELSHIKER MA, Bachtiger P, Petri CF, Nakhare S, et al
    Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
    Lancet. 2026 Jan 28:S0140-6736(25)02156-7. doi: 10.1016/S0140-6736(25)02156.
    PubMed     Abstract available
    
    
    
45. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    PubMed     Abstract available
    
    
    
46. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    PubMed     Abstract available
    
    
    December 2025
47. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
    TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
    Lancet. 2025;404:2593-2602.
    PubMed     Abstract available
    
    
    
48. TARANTINI G, Cardaioli F
    TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease.
    Lancet. 2025;404:2492-2493.
    PubMed    
    
    
    
49. TAVILDARI A, Dallenbach L, Sierro C, Jovic D, et al
    45-year follow-up after Gruntzig's coronary angioplasty.
    Lancet. 2025;406:2750.
    PubMed    
    
    
    November 2025
50. VAN DER BIJL P, Gulati M, Saraste A, Marwick T, et al
    Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.
    Lancet. 2025;406:2577-2587.
    PubMed     Abstract available
    
    
    
51. LEE JM
    Complete revascularisation in patients with acute myocardial infarction.
    Lancet. 2025 Nov 9:S0140-6736(25)02243-3. doi: 10.1016/S0140-6736(25)02243.
    PubMed    
    
    
    
52. MEHTA SR, Tiong DTW, Bohm F, Ramasundarahettige C, et al
    Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
    Lancet. 2025 Nov 9:S0140-6736(25)02170-1. doi: 10.1016/S0140-6736(25)02170.
    PubMed     Abstract available
    
    
    
53. SEFEROVIC PM, Polovina MM
    New perspectives on semaglutide in cardiovascular disease.
    Lancet. 2025;406:2198-2200.
    PubMed    
    
    
    
54. CAPODANNO D
    Three-month dual antiplatelet therapy after percutaneous coronary intervention: time for a new standard.
    Lancet. 2025;406:2196-2198.
    PubMed    
    
    
    
55. KANG J, Park KW, Han JK, Hwang D, et al
    Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
    Lancet. 2025;406:2244-2256.
    PubMed     Abstract available
    
    
    October 2025
56. GAO C, Onuma Y, Serruys PW, Tao L, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions - Authors' reply.
    Lancet. 2025;406:1951-1952.
    PubMed    
    
    
    
57. RISSANEN TT, Eccleshall S, Jeger R, Latib A, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950-1951.
    PubMed    
    
    
    
58. GURGOGLIONE FL, Cortese B
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1950.
    PubMed    
    
    
    
59. SPAULDING C, Eccleshall S, Krackhardt F, Urban P, et al
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949-1950.
    PubMed    
    
    
    
60. LIM PO
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1949.
    PubMed    
    
    
    
61. ZHOU T
    Drug-coated balloon angioplasty and stenting for coronary artery lesions.
    Lancet. 2025;406:1948-1949.
    PubMed    
    
    
    
62. HON JJ, Hon JKF
    Plant-based diets for coronary artery disease prevention.
    Lancet. 2025;406:1946-1947.
    PubMed    
    
    
    
63. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    PubMed     Abstract available
    
    
    August 2025
64. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
    beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
    PubMed     Abstract available
    
    
    
65. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
    PubMed     Abstract available
    
    
    
66. BYRNE RA, Coughlan JJ
    Immediate or staged complete revascularisation in patients with ST segment elevation myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01680-0. doi: 10.1016/S0140-6736(25)01680.
    PubMed    
    
    
    
67. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    PubMed     Abstract available
    
    
    
68. VERMA S, Leiter LA, Teoh H, Mancini GBJ, et al
    Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01633-2. doi: 10.1016/S0140-6736(25)01633.
    PubMed     Abstract available
    
    
    
69. GAUDINO M, Sandner S
    Evolocumab for prevention of coronary artery bypass failure: timing is everything.
    Lancet. 2025 Aug 28:S0140-6736(25)01718-0. doi: 10.1016/S0140-6736(25)01718.
    PubMed    
    
    
    
70. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    PubMed     Abstract available
    
    
    
71. VALGIMIGLI M, Choi KH, Giacoppo D, Gragnano F, et al
    Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
    Lancet. 2025 Aug 28:S0140-6736(25)01562-4. doi: 10.1016/S0140-6736(25)01562.
    PubMed     Abstract available
    
    
    
72. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    PubMed     Abstract available
    
    
    
73. LAM CSP, Cader FA, Chew NWS, Chow CK, et al
    Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission.
    Lancet. 2025 Aug 25:S0140-6736(25)01494-1. doi: 10.1016/S0140-6736(25)01494.
    PubMed    
    
    
    
74. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    PubMed     Abstract available
    
    
    July 2025
75. VRINTS C, Andreotti F
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:335.
    PubMed    
    
    
    
76. ANDERSEN BK, Escaned J, Christiansen EH, Holm NR, et al
    QFR vs FFR for intermediate coronary stenosis - Authors' reply.
    Lancet. 2025;406:335-336.
    PubMed    
    
    
    
77. KOMAMURA K, Miyake H, Kobayashi K, Ishiki R, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
78. ONUMA Y, Tsai TY, Sharif F, Wykrzykowska J, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
79. ZHU Q, Cheng Y, Wang S
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333-334.
    PubMed    
    
    
    
80. RODRIGUEZ-GRANILLO GA, Garcia-Garcia HM, Thierer J
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333.
    PubMed    
    
    
    June 2025
81. CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al
    The changing spectrum of cardiovascular diseases.
    Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990.
    PubMed    
    
    
    
82. THE LANCET
    From innovation to impact in cardiovascular disease.
    Lancet. 2025;405:2023.
    PubMed    
    
    
    May 2025
83. LEE SJ, Kim BK
    Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.
    Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827.
    PubMed    
    
    
    April 2025
84. HUANG C
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1463.
    PubMed    
    
    
    
85. VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al
    Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
    Lancet. 2025;405:1463-1464.
    PubMed    
    
    
    
86. APOSTOLOS A, Tsigkas G
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1462-1463.
    PubMed    
    
    
    
87. GUO C, Shan D, Liu Z, He F, et al
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1461-1462.
    PubMed    
    
    
    
88. ONIDA S, Davies AH
    Cardiovascular risk assessment in venous disease?
    Lancet. 2025;405:1141-1142.
    PubMed    
    
    
    March 2025
89. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    PubMed     Abstract available
    
    
    
90. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    PubMed     Abstract available
    
    
    
91. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    PubMed     Abstract available
    
    
    
92. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available
    
    
    
93. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    PubMed    
    
    
    
94. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    PubMed    
    
    
    
95. ROSSELLO X, Kristensen AMD
    Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
    Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562.
    PubMed    
    
    
    
96. ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al
    The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
    Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055.
    PubMed    
    
    
    
97. THE LANCET
    Rethinking coronary artery disease: a call to action.
    Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497.
    PubMed    
    
    
    
98. CHANDRASHEKHAR Y, Mensah G, Narula J
    From coronary artery disease to atherosclerotic coronary artery disease: what is in a name?
    Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563.
    PubMed    
    
    
    
99. WILSON C
    Nancy Brown: using advocacy to advance cardiovascular health.
    Lancet. 2025;405:688.
    PubMed    
    
    
    February 2025
100. XU C
     Inflammatory cardiovascular events and coronary artery disease.
     Lancet. 2025;405:545.
     PubMed    
     
     
     
101. CHAN K, Neubauer S, Channon KM, Deanfield J, et al
     Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
     Lancet. 2025;405:545-546.
     PubMed    
     
     
     
102. ZHAO K, Chen L, Sun Z
     Inflammatory cardiovascular events and coronary artery disease.
     Lancet. 2025;405:544.
     PubMed    
     
     
     
103. NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al
     Inflammatory cardiovascular events and coronary artery disease.
     Lancet. 2025;405:544-545.
     PubMed    
     
     
     January 2025
104. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
     Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
     Lancet. 2025;405:329-337.
     PubMed     Abstract available
     
     
     November 2024
105. LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al
     Cardiogenic shock.
     Lancet. 2024;404:2006-2020.
     PubMed     Abstract available
     
     
     October 2024
106. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
     Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
     Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
     PubMed     Abstract available
     
     
     
107. BECKER LM, Swaans MJ
     Present and future of functional measurements in coronary revascularisation.
     Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
     PubMed    
     
     
     
108. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
     Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
     Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
     PubMed     Abstract available
     
     
     
109. CAPODANNO D
     Coronary stenting with bioadaptors.
     Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
     PubMed    
     
     
     September 2024
110. THIELE H, Moller JE, Henriques JPS, Bogerd M, et al
     Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
     Lancet. 2024;404:1019-1028.
     PubMed     Abstract available
     
     
     
111. NORDESTGAARD BG, Langsted A
     Lipoprotein(a) and cardiovascular disease.
     Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308.
     PubMed     Abstract available
     
     
     August 2024
112. KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al
     The Lancet-JACC collaboration: advancing cardiovascular health.
     Lancet. 2024;404:833-834.
     PubMed    
     
     
     
113. JENTZER JC, Hibbert B
     Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock.
     Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588.
     PubMed    
     
     
     
114. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
     Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
     Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
     PubMed     Abstract available
     
     
     
115. MAMAS MA, Mintz GS
     Optical coherence tomography imaging for complex percutaneous coronary intervention.
     Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
     PubMed    
     
     
     
116. GAO C, He X, Ouyang F, Zhang Z, et al
     Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
     Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
     PubMed     Abstract available
     
     
     
117. MCENTEGART MB, Kirtane AJ
     How feasible is a cage-free solution for de novo coronary artery disease?
     Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696.
     PubMed    
     
     
     
118. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
     De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
     Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
     PubMed     Abstract available
     
     
     
119. STEFANINI GG, Oliva A
     Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
     Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678.
     PubMed    
     
     
     
120. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
     Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
     Lancet. 2024;404:773-786.
     PubMed     Abstract available
     
     
     June 2024
121. LIU J, Li Y, Ge J, Yan X, et al
     Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
     Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
     PubMed     Abstract available
     
     
     
122. GAO Y, Li Z, Liu M, Tian J, et al
     VA-ECMO for infarct-related cardiogenic shock.
     Lancet. 2024;403:2487.
     PubMed    
     
     
     
123. YU Z, Li G
     VA-ECMO for infarct-related cardiogenic shock.
     Lancet. 2024;403:2487.
     PubMed    
     
     
     
124. ZEYMER U, Freund A, Hochadel M, Schneider S, et al
     VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
     Lancet. 2024;403:2487-2488.
     PubMed    
     
     
     
125. LI Y
     VA-ECMO for infarct-related cardiogenic shock.
     Lancet. 2024;403:2486.
     PubMed    
     
     
     
126. DALZELL JR
     VA-ECMO for infarct-related cardiogenic shock.
     Lancet. 2024;403:2486.
     PubMed    
     
     
     
127. WANG G, Guan J, Liu Z
     VA-ECMO for infarct-related cardiogenic shock.
     Lancet. 2024;403:2485.
     PubMed    
     
     
     
128. KELLY P, Lemmens R, Weimar C, Walsh C, et al
     Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
     Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
     PubMed     Abstract available
     
     
     May 2024
129. CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al
     Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
     Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596.
     PubMed     Abstract available
     
     
     
130. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
     Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
     Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
     PubMed     Abstract available
     
     
     April 2024
131. FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al
     Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
     Lancet. 2024;403:1543-1553.
     PubMed     Abstract available
     
     
     
132. MONTI CB, Palmisano A
     Coronary sinus reducer: a new hope for refractory angina?
     Lancet. 2024;403:1514-1515.
     PubMed    
     
     
     
133. LI X, Ge Z, Kan J, Anjum M, et al
     Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
     Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
     PubMed     Abstract available
     
     
     
134. DEN DEKKER WK
     Is intravascular imaging the future of percutaneous coronary intervention?
     Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
     PubMed    
     
     
     
135. GE Z, Kan J, Gao X, Raza A, et al
     Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
     Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
     PubMed     Abstract available
     
     
     
136. STEINER-GAGER GM, Siller-Matula JM
     Abbreviated dual antiplatelet therapy after acute coronary syndrome.
     Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
     PubMed    
     
     
     
137. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
     Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
     Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
     PubMed     Abstract available
     
     
     
138. BOROVAC JA
     Percutaneous coronary intervention for non-obstructive vulnerable plaques.
     Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
     PubMed    
     
     
     March 2024
139. RIDKER PM, Bhatt DL, Nissen SE
     Inflammation, infection, and cardiovascular risk - Authors' reply.
     Lancet. 2024;403:1025-1026.
     PubMed    
     
     
     
140. SHARMA S, Sharma R
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1024-1025.
     PubMed    
     
     
     
141. GOLDMAN M, Bondue A, Cogan E
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1023.
     PubMed    
     
     
     
142. GOLDSTEIN MR, Mascitelli L
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1023-1024.
     PubMed    
     
     
     
143. DROZD M, Cubbon R
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1022-1023.
     PubMed    
     
     
     
144. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1022.
     PubMed    
     
     
     
145. STRANDBERG TE, Kovanen PT, Gylling H
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1021.
     PubMed    
     
     
     
146. LIN GM, Huang WC, Han CL
     Inflammation, infection, and cardiovascular risk.
     Lancet. 2024;403:1021-1022.
     PubMed    
     
     
     February 2024
147. LEE ZS, Ryan N
     Intravascular imaging in percutaneous coronary intervention.
     Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
     PubMed    
     
     
     
148. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
     Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
     Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum